Charles Schwab Investment Management Inc. Has $12.79 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Charles Schwab Investment Management Inc. raised its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 17.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,940,680 shares of the company's stock after acquiring an additional 288,926 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.69% of Recursion Pharmaceuticals worth $12,789,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new position in Recursion Pharmaceuticals during the 3rd quarter valued at about $25,000. Farther Finance Advisors LLC raised its stake in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after buying an additional 4,091 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock worth $48,000 after buying an additional 6,036 shares during the period. KBC Group NV increased its holdings in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after acquiring an additional 3,377 shares during the period. Finally, Amalgamated Bank increased its holdings in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after acquiring an additional 2,459 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX traded up $0.26 during midday trading on Monday, hitting $8.27. The company's stock had a trading volume of 34,263,745 shares, compared to its average volume of 12,371,136. The company has a market cap of $2.37 billion, a P/E ratio of -5.24 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $15.74. The business's 50 day simple moving average is $6.61 and its 200 day simple moving average is $7.31. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million for the quarter, compared to analysts' expectations of $12.62 million. During the same period last year, the firm earned ($0.43) earnings per share. Recursion Pharmaceuticals's revenue for the quarter was up 147.6% on a year-over-year basis. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00. Following the completion of the transaction, the chief financial officer now owns 1,377,756 shares in the company, valued at $8,500,754.52. The trade was a 1.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Gibson sold 20,000 shares of the business's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the transaction, the chief executive officer now owns 762,656 shares of the company's stock, valued at approximately $4,697,960.96. The trade was a 2.56 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,235 shares of company stock worth $895,538. 15.75% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RXRX. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research note on Tuesday, September 3rd. Jefferies Financial Group decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.